SOAT1 and rheumatoid arthritis: Notably, the Tofacitinib group exhibited a marked reduction in JAK–STAT pathway activity, consistent with its known pharmacological mechanism as a JAK inhibitor, which effectively inhibits cytokine-mediated signal transduction, thereby alleviating synovitis and joint deterioration in RA.